Dopamine-frusemide therapy in acute renal failure.

G. Graziani, S. Casati, A. Cantaluppi, A. Citterio, A. Aroldi, A. Scalamogna, D. Brancaccio, C. Ponticelli

Research output: Contribution to journalArticle

Abstract

In 16 patients with ARF and in three with hepatorenal syndrome we infused dopamine (3 micrograms/kg/min) and frusemide (10-15 mg/kg/day) for 6-24 hours. This treatment produced in all patients a significant diuresis and natriuresis without any modification of blood pressure, pulse rate, and central venous pressure. In three patients with hepatorenal syndrome diuresis was established during dopamine and frusemide infusion, but severe oliguria again reappeared when drug infusion was stopped. This experience suggests that this therapy may avoid fluid overload and hyperkalaemia in oliguric patients reducing the need for dialysis. It is also the first successful approach in the treatment of hepatorenal syndrome although its effect is transient.

Original languageEnglish
Pages (from-to)319-324
Number of pages6
JournalProceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association
Volume19
Publication statusPublished - 1983

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Graziani, G., Casati, S., Cantaluppi, A., Citterio, A., Aroldi, A., Scalamogna, A., Brancaccio, D., & Ponticelli, C. (1983). Dopamine-frusemide therapy in acute renal failure. Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association, 19, 319-324.